Dendritic cells loaded with polyomavirus VP1/VP2Her2 virus-like particles efficiently prevent outgrowth of a Her2/neu expressing tumor

Cancer Immunology, Immunotherapy

Volumn 56, Issue 9, 2007, Pages 1335-1344

  Tegerstedt, Karin ^a   Franzén, Andrea ^a   Ramqvist, Torbjörn ^a   Dalianis, Tina ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Breast cancer; Her2; Polyomavirus and immunotherapy; Virus like particle

Indexed keywords

DENDRITIC CELL VACCINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 2[1-683]; INTERLEUKIN 12; PROTEIN VP1; PROTEIN VP2; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG; VIRUS ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ARTICLE; CANCER IMMUNOTHERAPY; CELL MATURATION; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IMMUNIZATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; TUMOR IMMUNITY; VIRUS LIKE AGENT;

ANIMALS; CANCER VACCINES; CAPSID PROTEINS; CELL LINE; DENDRITIC CELLS; FEMALE; HUMANS; INTERLEUKIN-12; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; PEPTIDE FRAGMENTS; RECEPTOR, ERBB-2; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES;

EID: 34347387533     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-007-0281-8     Document Type: Article

References (24)

1. Boisgerault F, Moron G, Leclerc C (2002) Virus-like particles: a new family of delivery systems. Expert Rev Vaccines 1:101-109
2. Boura E, Liebl D, Spisek R, Fric J, Marek M, Stokrova J, Holan V, Forstova J (2005) Polyomavirus EGFP-pseudocapsids: analysis of model particles for introduction of proteins and peptides into mammalian cells. FEBS Lett 579:6549-6558
3. Bungener L, Idema J, ter Veer W, Huckriede A, Daemen T, Wilschut J (2002) Virosomes in vaccine development: induction of cytotoxic T lymphocyte activity with virosome-encapsulated protein antigens. J Liposome Res 12:155-163
4. Da Silva DM, Schiller JT, Kast WM (2003) Heterologous boosting increases immunogenicity of chimeric papillomavirus virus-like particle vaccines. Vaccine 21:3219-3227
5. Di Carlo E, Diodoro MG, Boggio K, Modesti A, Modesti M, Nanni P, Forni G, Musiani P (1999) Analysis of mammary carcinoma onset and progression in HER-2/neu oncogene transgenic mice reveals a lobular origin. Lab Invest 79:1261-1269
6. Disis ML, Smith JW, Murphy AE, Chen W, Cheever MA (1994) In vitro generation of human cytolytic T-cells specific for peptides derived from the HER-2/neu protooncogene protein. Cancer Res 54:1071-1076
7. Forstova J, Krauzewicz N, Sandig V, Elliott J, Palkova Z, Strauss M, Griffin BE (1995) Polyoma virus pseudocapsids as efficient carriers of heterologous DNA into mammalian cells. Hum Gene Ther 6:297-306
8. Greenstone HL, Nieland JD, de Visser KE, De Bruijn ML, Kirnbauer R, Roden RB, Lowy DR, Kast WM, Schiller JT (1998) Chimeric papillomavirus virus-like particles elicit antitumor immunity against the E7 oncoprotein in an HPV16 tumor model. Proc Natl Acad Sci USA 95:1800-1805
9. Harper DM, Franco EL, Wheeler C, Ferris DG, Jenkins D, Schuind A, Zahaf T, Innis B, Naud P, De Carvalho NS, Roteli-Martins CM, Teixeira J, Blatter MM, Korn AP, Quint W, Dubin G (2004) Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 364:1757-1765
10. Kiessling R, Wei WZ, Herrmann F, Lindencrona JA, Choudhury A, Kono K, Seliger B, (2002) Cellular immunity to the Her-2/neu protooncogene. Adv Cancer Res 85:101-144
11. Koutsky LA, Ault KA, Wheeler CM, Brown DR, Barr E, Alvarez FB, Chiacchierini LM, Jansen KU (2002) A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 347:1645-1651
12. Lenz P, Day PM, Pang YY, Frye SA, Jensen PN, Lowy DR, Schiller JT (2001) Papillomavirus-like particles induce acute activation of dendritic cells. J Immunol 166:5346-5355
13. Lutz MB, Kukutsch N, Ogilvie AL, Rossner S, Koch F, Romani N, Schuler G (1999) An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. J Immunol Methods 223:77-92
14. Macatonia SE, Hosken NA, Litton M, Vieira P, Hsieh CS, Culpepper JA, Wysocka M, Trinchieri G, Murphy KM, O'Garra A (1995) Dendritic cells produce IL-12 and direct the development of Th1 cells from naive CD4+ T cells. J Immunol 154:5071-5079
15. Neijssen J, Herberts C, Drijfhout JW, Reits E, Janssen L, Neefjes J (2005) Cross-presentation by intercellular peptide transfer through gap junctions. Nature 434:83-88
16. Osborne CK, Bardou V, Hopp TA, Chamness GC, Hilsenbeck SG, Fuqua SA, Wong J, Allred DC, Clark GM, Schiff R (2003) Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. J Natl Cancer Inst 95:353-361
17. Piechocki MP, Pilon SA, Kelly C, Wei WZ (2001) Degradation signals in ErbB-2 dictate proteasomal processing and immunogenicity and resist protection by cis glycine-alanine repeat. Cell Immunol 212:138-149
18. Pupa SM, Menard S, Andreola S, Colnaghi MI (1993) Antibody response against the c-erbB-2 oncoprotein in breast carcinoma patients. Cancer Res 53:5864-5866
19. Rose RC, Bonnez W, Reichman RC, Garcea RL (1993). Expression of human papillomavirus type 11 L1 protein in insect cells: in vivo and in vitro assembly of viruslike particles. J Virol 67:1936-1944
20. Schuurhuis DH, van Montfoort N, Ioan-Facsinay A, Jiawan R, Camps M, Nouta J, Melief CJ, Verbeek JS, Ossendorp F (2006) Immune complex-loaded dendritic cells are superior to soluble immune complexes as antitumor vaccine. J Immunol 176:4573-4580
21. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177-182
22. Tegerstedt K, Andreasson K, Vlastos A, Hedlund KO, Dalianis T, Ramqvist T (2003) Murine pneumotropic virus VP1 virus-like particles (VLPs) bind to several cell types independent of sialic acid residues and do not serologically cross react with murine polyomavirus VP1 VLPs. J Gen Virol 84:3443-3452
23. Tegerstedt K, Lindencrona JA, Curcio C, Andreasson K, Tullus C, Forni G, Dalianis T, Kiessling R, Ramqvist T (2005) A single vaccination with polyomavirus VP1/VP2Her2 virus-like particles prevents outgrowth of HER-2/neu-expressing tumors. Cancer Res 65:5953-5957
24. Vlastos A, Andreasson K, Tegerstedt K, Hollanderova D, Heidari S, Forstova J, Ramqvist T, Dalianis T (2003) VP1 pseudocapsids, but not a glutathione-S-transferase VP1 fusion protein, prevent polyomavirus infection in a T-cell immune deficient experimental mouse model. J Med Virol 70:293-300